Zevra Therapeutics financials
$11.34+0.35%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $39.7M | $36.2M | $34.1M | $26.1M | $25.9M | $20.4M | $12.0M | $3.7M | $4.4M | $3.4M | $12.9M | $2.9M |
| Gross profit | $38.1M | $34.3M | $32.6M | $24.8M | $13.5M | $19.1M | $10.7M | $1.4M | $876.0K | $3.3M | $11.7M | $2.8M |
| Gross margin | 96.2% | 94.8% | 95.5% | 95.3% | 52.2% | 93.4% | 88.7% | 37.7% | 19.7% | 94.9% | 90.5% | 95.0% |
| Operating income | $16.8M | $8.8M | $9.3M | $4.1M | -$71.0M | -$5.4M | -$15.4M | -$27.3M | -$23.8M | -$20.5M | -$15.2M | -$15.4M |
| Net income | $8.4M | $37.9M | $12.2M | -$544.0K | $67.9M | -$3.1M | -$35.7M | -$33.2M | -$19.9M | -$16.6M | -$19.9M | -$10.4M |
| Net margin | 21.2% | 104.6% | 35.6% | −2.1% | 262.4% | −15.2% | −296.8% | −899.2% | −447.9% | −485.3% | −154.0% | −358.1% |
| Diluted EPS | $0.14 | $0.60 | $0.19 | $-0.01 | $1.21 | $-0.06 | $-0.67 | $-0.69 | $-0.48 | $-0.40 | $-0.51 | $-0.30 |
| EBITDA | $17.1M | $9.2M | -$49.0M | $63.2M | -$10.7M | -$3.7M | -$13.8M | -$25.7M | -$22.2M | -$18.9M | -$14.4M | -$15.3M |
| Operating cash flow | $17.0M | $6.1M | $5.5M | $4.7M | -$3.6M | -$8.2M | -$16.3M | -$18.1M | -$19.1M | -$16.2M | -$16.2M | -$4.6M |
| Free cash flow | $16.8M | $6.1M | $5.5M | $4.2M | -$3.8M | -$8.3M | -$16.3M | -$18.1M | -$19.1M | -$16.2M | -$16.2M | -$4.8M |
| Diluted shares | 61.3M | 60.2M | 62.7M | 56.0M | 56.3M | 54.1M | 53.5M | 47.8M | 41.9M | 41.8M | 38.7M | 34.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $145.3M | $95.6M | $62.4M | $54.4M | $47.7M | $37.3M |
| Short-term investments | $76.2M | $105.0M | $128.6M | $145.1M | $154.9M | $25.3M |
| Total debt | $0.00 | $13.2M | $61.9M | $61.3M | $60.7M | $60.1M |
| Total assets | $302.7M | $278.6M | $284.7M | $270.1M | $256.3M | $172.7M |
| Total liabilities | $85.1M | $72.8M | $130.1M | $137.0M | $139.0M | $131.7M |
| Shareholders' equity | $217.7M | $205.8M | $154.7M | $133.2M | $117.2M | $41.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology